Grab your favorite coffee. This is where you’ll find all the substance you require, and more.

Cognivia-Narrow-Hero-1
Insights

The Behavioral Layer: An Overlooked Determinant of Clinical Success 

Clinical research continues to evolve at an impressive pace. Digital technologies streamline data capture, biomarkers deepen biological insight, and innovative trial designs broaden access for diverse populations. These advances have unquestionably accelerated development and expanded participant reach. Still, across all this progress, one dimension consistently shapes…

Read More
Insights

Discussion on the Use of Placebell and FDA’s Feedback

Cognivia recently initiated a discussion with the FDA through the “Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program” process. A Letter of Intent (LOI) was…

Read More
Insights

Disruptive Technology Without the Disruption

Implementing an innovative technology within a clinical trial is about much, much more than the technology – and while the tech might be “disruptive,” its actual implementation…

Read More
Insights

A “Unik” Approach to Capturing and Managing Patient Data

How the drive to maximize valuable data while minimizing patient and study team burden resulted in a unique data collection and management platform. Patient engagement is a…

Read More
Insights

A New Era of Cognivia

Innovation, evolution and agility have always been core elements of drug and device development. How else, but through creative, out-of-the-box thinking and a willingness to innovate have…

Read More
Insights

Innovation with Integrity

It has taken a decade of scientific integrity and rigor – and a very particular mindset – for Cognivia to develop its current suite of innovative solutions….

Read More

Understand patient differences in your next clinical trial

Increase your trial’s success rates and bring new therapies to patients faster.

Tell us about your clinical trial below, and our team will be in touch.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.